Efficacy and Tolerability of Agents in the Long-Acting GLP-1R
The study evaluated two once-weekly GLP-1R agonists, semaglutide and dulaglutide, at both low and high approved doses, in about 1,200 patients with type 2 diabetes not well controlled with metformin. With more evidence of variability in efficacy and tolerability of agents in the long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist class of diabetes medicines. The study is been published in The Lancet Diabetes & Endocrinology.